News MSD's $349m alliance with Variational, and other AI news MSD signs $345m alliance with Variational AI, plus updates on AI in drug discovery projects from Bio Protocol, Dalton Tx, Virginia Tech, and Insilico.
News NHS cleared to use Astellas' non-hormonal menopause drug Around half a million women will soon be able to access Astellas' Veoza treatment for symptoms like hot flushes associated with menopause.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.